Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial

Worsening heart failure (WHF) symptoms despite initial therapy during admission for acute heart failure (AHF) is associated with worse outcomes. The association between the time of the WHF event and the intensity of WHF therapy with outcomes is unknown.

[1]  C. O'connor,et al.  Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study , 2014, European journal of heart failure.

[2]  Laura G. Qualls,et al.  In‐Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization , 2014, Journal of the American Heart Association.

[3]  P. Ponikowski,et al.  International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short‐term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial , 2014, European journal of heart failure.

[4]  B. Massie,et al.  Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. , 2013, JACC. Heart failure.

[5]  P. Ponikowski,et al.  Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.

[6]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[7]  P. Ponikowski,et al.  The PROTECT in‐hospital risk model: 7‐day outcome in patients hospitalized with acute heart failure and renal dysfunction , 2012, European journal of heart failure.

[8]  P. Ponikowski,et al.  Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.

[9]  P. Ponikowski,et al.  Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. , 2010, Journal of cardiac failure.

[10]  P. Ponikowski,et al.  Physician-Determined Worsening Heart Failure: A Novel Definition for Early Worsening Heart Failure in Patients Hospitalized for Acute Heart Failure – Association with Signs and Symptoms, Hospitalization Duration, and 60-Day Outcomes , 2009, Cardiology.

[11]  I. Kobrin,et al.  Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome. , 2009, Journal of cardiac failure.

[12]  C. O'connor,et al.  Early worsening heart failure in patients admitted with acute heart failure – a new outcome measure associated with long‐term prognosis? , 2009, Fundamental & clinical pharmacology.

[13]  H. Hillege,et al.  Cardiac Resynchronization Therapy Improves Renal Function , 2009 .

[14]  C. O'connor,et al.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. , 2007, JAMA.

[15]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.